Source: Fortune.com
Summary
Novo Nordisk CEO Mike Doustdar says the company’s obesity drugs, Ozempic and Wegovy, could lead to new areas of healthcare, including longevity research and aesthetic medicine. Doustdar stated that the main ingredient, semaglutide, may have benefits beyond weight loss, such as protecting vital organs. The company is exploring these possibilities while facing pressure from investors to expand its focus beyond diabetes and obesity treatments. Novo’s shares have fallen 12.7% this year due to pricing pressure and competition.
Our Reading
The strategy enters a familiar phase.
Novo Nordisk’s Mike Doustdar is reframing the company’s focus on obesity and diabetes treatments, exploring new areas like longevity research and aesthetic medicine. The company’s scientists are now looking beyond weight loss to identify other diseases that future GLP-1 drugs could remedy. Eli Lilly, a competitor, has already expanded its portfolio to include oncology, immunology, and neuroscience. Novo’s shares have fallen significantly this year, and analysts sense that change is afoot under Doustdar’s leadership.
The company’s “obsession” with patient needs may lead it to invest in areas like skincare and hair loss, which have become intertwined with the rise of weight-loss drugs.
Author: Evan Null
